IP Library Granted Patent US 11,421,202
Granted Patent B2
US 11,421,202 · App. 16/816,641 · Granted Aug 23, 2022

Virus filtration of cell culture media

Inventors: Wolfgang Mundt (Vienna, AT); Artur Mitterer (Orth/Donau, AT); Manfred Reiter (Vienna, AT); Meinhard Hasslacher (Vienna, AT); Leopold Grillberger (Vienna, AD); Thomas Kreil (Klosterneuburg, AT)
Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
C12N5/0602A61L2/0017C12M29/26C12M37/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,421,202
App. No.
16/816,641
Granted
Aug 23, 2022
Kind
B2
Abstract

The invention relates to a method for removing a viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. The method comprises subjecting said preparation to filtration for at least about 24 hours through a virus filter having an effective pore size of maximum about 75 nm. Further, the invention relates to the use of a virus filter in filtration of at least about 24 hours, wherein the virus filter has an effective pore size of maximum about 75 nm for the removal of viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. In some embodiments the filtration according to the invention operates at a volumetric capacity of at least about 2000 L/m 2 . Further, the invention relates to the use of a preparation, being a cell culture medium or at least a component of a cell culture medium obtainable according to method of the invention for cell culture; pharmaceutical, diagnostic and/or cosmetic preparations as well as in food preparations.

Claims (57)

1. A method for removing a viral contaminant from a liquid preparation comprising the steps of:

supplying a liquid preparation to at least one replaceable virus filter having an effective pore size of 5-75 nm, wherein the virus filter is in fluid communication with a bioreactor; and

removing a viral contaminant by filtering the preparation through the virus filter, under pressure, for a minimum total run time of about 24 hours; and

collecting the filtered preparation;

wherein the preparation comprises a cell culture medium or at least one component thereof; the virus filter is not replaced during the minimum run time; the pressure is from about 100 mbar to about 4000 mbar; and filtration operates at a volumetric capacity of at least about 2000 L/m 2 .

2. The method of claim 1 , wherein the bioreactor is a chemostat reactor, a perfusion reactor, or a fed batch reactor.

3. The method of claim 1 , wherein the virus filter comprises two or more virus filters arranged in series, in parallel, or both.

4. The method of claim 3 , wherein the virus filter comprises two virus filters arranged in parallel in a system of feed lines comprising a Y-shaped junction and wherein each virus filter is in fluid communication with a branch of the Y-shaped junction.

5. The method of claim 1 , wherein the virus filter is autoclavable.

6. The method of claim 1 , wherein the preparation comprises a soy hydrolysate.

7. The method of claim 1 , wherein the preparation comprises animal derived components.

8. The method of claim 1 , wherein the volumetric capacity is at least about 3000 L/m 2 .

9. The method of claim 1 , wherein the total run time is at least about 48 hours.

10. The method of claim 1 , wherein the filtration is continuous filtration.

11. The method of claim 1 , wherein the filtering provides at least a 4 Log 10 reduction value (LRV) for the viral contaminant.

12. The method of claim 1 , wherein the filtration is performed at a pressure ranging from about 1000 mbar to about 3000 mbar.

13. The method of claim 1 , wherein the virus filter has an effective pore size of 15-75 nm.

14. The method of claim 13 , wherein the pressure is from about 1000 mbar to about 3000 mbar.

15. The method of claim 14 , wherein the filtering provides at least a 4 Log 10 reduction value (LRV) for the viral contaminant.

16. The method of claim 15 , wherein the filtration is continuous filtration.

17. The method of claim 15 , wherein the volumetric capacity is at least about 3000 L/m 2 .

18. The method of claim 16 , wherein the volumetric capacity is at least about 3000 L/m 2 .

19. The method of claim 1 , wherein the effective pore size is 15-35 nm.

20. The method of claim 14 , wherein the effective pore size is 15-35 nm.

21. A method for removing a viral contaminant from a liquid preparation comprising a cell culture medium or at least one component thereof, the method comprising the steps of:

supplying a liquid preparation to two or more replaceable virus filters arranged in series, in parallel, or both, wherein each virus filter is in fluid communication with a bioreactor and each virus filter has an effective pore size of 15-75 nm; and

removing a viral contaminant by filtering the preparation through the virus filters, under pressure, for a minimum total run time of at least about 24 hours per virus filter; and

collecting the filtered preparation;

wherein no virus filter is replaced during its minimum run time; the pressure is from about 100 mbar to about 2000 mbar; and filtration operates at a volumetric capacity of at least about 2000 L/m 2 .

22. The method of claim 21 , wherein the two or more replaceable virus filters comprises two virus filters arranged in parallel in a system of feed lines comprising a Y-shaped junction and wherein each virus filter is in fluid communication with a branch of the Y-shaped junction.

23. The method of claim 22 , wherein the system of feed lines is upstream of the bioreactor.

24. The method of claim 22 , wherein the filtration is continuous filtration.

25. The method of claim 22 , wherein the filtration is batch filtration.

26. The method of claim 21 , wherein the filtration is performed at a temperature of from about 10° C. to about 40° C.

27. The method of claim 21 , wherein the filtration is performed at ambient temperature.

28. The method of claim 21 , further comprising the step of replacing each virus filter that exceeds a predetermined pressure differential.

29. The method of claim 28 , wherein the predetermined pressure differential is about 2000 mbar.

30. The method of claim 21 , wherein the total run time of each virus filter is at least about 48 hours.

31. The method of claim 21 , wherein the total run time of each virus filter is at least about 72 hours.

32. The method of claim 21 , wherein the total run time of each virus filter is at least about 1 week.

33. The method of claim 21 , wherein the total run time of each virus filter is at least about 4 weeks.

34. The method of claim 21 , wherein the total run time of each virus filter is at least about 2 months.

35. The method of claim 21 , wherein a total volumetric capacity per virus filter, without replacement, is at least about 4000 L/m 2 .

36. The method of claim 21 , wherein a total volumetric capacity per virus filter, without replacement, is at least about 5000 L/m 2 .

37. The method of claim 21 , wherein a total volumetric capacity per virus filter, without replacement, is at least about 7500 L/m 2 .

38. The method of claim 21 , wherein a total volumetric capacity per virus filter, without replacement, is at least about 10,000 L/m 2 .

39. The method of claim 21 , wherein a total volumetric capacity per virus filter, without replacement, is at least about 20,000 L/m 2 .

40. The method of claim 1 , wherein a specific flow rate of each virus filter is from about 5 L/(m 2 ×hr) to about 500 L/(m 2 ×hr).

41. The method of claim 21 , wherein a specific flow rate of each virus filter is from about 5 L/(m 2 ×hr) to about 500 L/(m 2 ×hr).

42. The method of claim 1 , wherein at least two virus filters are arranged in parallel in a system of feed lines, the effective pore size of each virus filter is 15-35 nm, filtration is performed at a pressure of at least 100 mbar and a temperature of from about 10° C. to about 40° C., and a specific flow rate of each virus filter is from about 5 L/(m 2 ×hr) to about 500 L/(m 2 ×hr).

43. The method of claim 42 , wherein the system of feed lines is upstream of the bioreactor, the filtration is continuous filtration, the run time is at least about 4 weeks, the volumetric capacity is at least about 5000 L/m 2 , and the filtering provides at least a 4 Log 10 reduction value (LRV) for the viral contaminant.

44. The method of claim 21 , wherein at least two virus filters are arranged in parallel in a system of feed lines, the effective pore size of each virus filter is 15-35 nm, filtration is performed at a pressure of at least 100 mbar and a temperature of from about 10° C. to about 40° C., and a specific flow rate of each virus filter is from about 5 L (m 2 ×hr) to about 500 L (m 2 ×hr).

45. The method of claim 44 , wherein the system of feed lines is upstream of the bioreactor, the bioreactor has a capacity of at least about 2000 L, the filtration is continuous filtration, the run time is at least about 4 weeks, the volumetric capacity is at least about 5000 L/m 2 , and the filtering provides at least a 4 Log 10 reduction value (LRV) for the viral contaminant.

46. The method of claim 43 , wherein the filtration is crossflow filtration.

47. The method of claim 45 , wherein the filtration is crossflow filtration.

48. The method of claim 43 , wherein the filtration is dead end filtration.

49. The method of claim 45 , wherein the filtration is dead end filtration.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 056231/0250 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2020
From: MUNDT, WOLFGANG; MITTERER, ARTUR; REITER, MANFRED; HASSLACHER, MEINHARD; GRILLBERGER, LEOPOLD; KREIL, THOMAS
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 052636/0318 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2020
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 052637/0063 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2020
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 052646/0001 →
Continuity (4)
Continuation 15470064 · Mar 27, 2017
Division 13921417 · Jun 19, 2013
Provisional Application 61662814 · Jun 21, 2012
Related Publication 20200277565A1 · Sep 3, 2020